NPM1 and leukemia: Indeed, NPM1-mutated C-terminal aminoacidic sequences are not found in either malignancies different from AML or normal tissues, resulting in leukemia-specific neoantigens considered optimal target for immunotherapy [2,3,15,16,19,20,88,89].